Table 5.
Correlation between clinicopathological characteristics and OPRM1 methylation in breast tumor tissue DNA and peripheral blood leukocyte DNA.
| Character of clinical pathology | Tumor tissue DNA | Peripheral blood leukocyte DNA. | ||||||
|---|---|---|---|---|---|---|---|---|
| Hypermethylated no. (%) | Hypomethylated no. (%) | ORcrude (95%CI)a | P-value | Hypermethylated no. (%) | Hypomethylated no. (%) | ORcrude (95%CI)a | P-value | |
| TNM stages | ||||||||
| I | 44 (23.5) | 45 (24.2) | 1.000 | 24 (35.8) | 90 (33.3) | 1.000 | ||
| II | 96 (51.3) | 98 (52.7) | 1.002 (0.607–1.655) | 0.994 | 37 (55.2) | 153 (56.7) | 1.103 (0.620–1.961) | 0.739 |
| III–IV | 47 (25.1) | 43 (23.1) | 1.118 (0.622–2.009) | 0.701 | 6 (9.0) | 27 (10.0) | 1.200 (0.445–3.238) | 0.719 |
| Tumor invasion | ||||||||
| T1 | 61 (32.6) | 78 (42.2) | 1.000 | 126 (46.7) | 31 (46.3) | 1.000 | ||
| T2–T4 | 126 (67.4) | 107 (57.8) | 1.506 (0.987–2.298) | 0.058 | 144 (53.3) | 36 (53.7) | 0.984 (0.576–1.683) | 0.953 |
| Lymphnodes involved | ||||||||
| N0 | 98 (52.4) | 102 (54.8) | 1.000 | 134 (49.8) | 30 (44.8) | 1.000 | ||
| N1/N2 | 89 (47.6) | 84 (45.2) | 1.103 (0.734–1.657) | 0.638 | 135 (50.2) | 37 (55.2) | 0.817 (0.477–1.398) | 0.461 |
| Metastasis status | ||||||||
| M0 | 177 (94.7) | 180 (96.8) | 1.000 | 258 (95.6) | 63 (96.9) | 1.000 | ||
| M1 | 10 (5.3) | 6 (3.2) | 1.695 (0.603–4.763) | 0.317 | 12(4.4) | 2(3.1) | 1.465 (0.320–6.713) | 0.623 |
| Histological type | ||||||||
| Non-invasive | 48 (25.8) | 48 (28.3) | 1.000 | 18 (6.9) | 3 (4.5) | 1.000 | ||
| Invasive | 138 (47.2) | 138 (71.7) | 1.000 (0.628–1.591) | 1.000 | 243 (93.1) | 63 (95.5) | 1.556 (0.444–5.447) | 0.490 |
| ER status | ||||||||
| Positive | 134 (72.0) | 106 (57.0) | 1.000 | 15 (7.1) | 4 (7.8) | 1.000 | ||
| Negative | 52 (28.0) | 80 (43.0) | 1.945 (1.262–2.996) | 0.003 | 196 (92.9) | 47 (92.2) | 1.112 (0.353–3.505) | 0.856 |
| PR status | ||||||||
| Positive | 109 (58.6) | 87 (46.8) | 1.000 | 19 (9.9) | 6 (12.2) | 1.000 | ||
| Negative | 77 (41.4) | 99 (53.2) | 1.611 (1.069–2.427) | 0.023 | 173 (90.1) | 43 (87.8) | 1.271 (0.478–3.3.74) | 0.613 |
| HER2 expression | ||||||||
| Positive | 124 (66.7) | 124 (67.0) | 1.000 | 13 (6.4) | 8 (20.0) | 1.000 | ||
| Negative | 62 (33.3) | 61 (33.0) | 1.061 (0.660–1.566) | 0.941 | 191 (93.6) | 32 (80.0) | 3.673 (1.411–9.564) | 0.008 |
| Molecular subtype b | ||||||||
| Luminal A | 24 (12.9) | 25 (13.5) | 1.000 | 2 (1.4) | 1 (3.1) | 1.000 | ||
| Luminal B | 38 (20.4) | 36 (19.5) | 1.100 (0.534–2.264) | 0.797 | 11 (7.9) | 7 (21.9) | 0.786 (0.059–10.377) | 0.855 |
| HER-2 enriched | 98 (52.7) | 72 (38.9) | 0.418 (0.750–2.682) | 0.283 | 114 (81.4) | 21 (65.6) | 2.714 (0.235–31.302) | 0.423 |
| Basal-like | 26 (14.0) | 52 (28.1) | 0.521 (0.251–1.083) | 0.810 | 13 (9.3) | 3 (9.4) | 2.167 (0.144–35.528) | 0.576 |
| P53 | ||||||||
| Negative | 127 (69.8) | 112 (71.7) | 1.000 | 34 (33.0) | 12 (36.4) | 1.000 | ||
| Positive | 55 (30.2) | 52 (28.3) | 1.099 (0.701–1.725) | 0.680 | 69 (67.0) | 21 (63.6) | 1.160 (0.511–3.632) | 0.723 |
a
ORcrude, odds ratio generated by univariate logistic regression; 95%CI, 95% confidence interval.
b
Subtypes were classified by immunohistochemically surrogates as basal-like (ER-, PR-, HER-2–, triple-negative), luminal A (ER and/or PR+, HER-2–), luminal B (ER and/or PR+, HER-2+), or HER-2 enriched (ER and PR–, HER-2+).
The bold values represent the results with statistical significance.